Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the safety and efficacy of ABLC versus oral
Posaconazole in the prevention of invasive fungal infections in high risk patients with
hematologic malignancies or hematopoietic stem cell transplant.
Primary objective is to demonstrate the low toxicity rate and low rate of invasive fungal
infections associated with ABLC or Posaconazole prophylaxis.
Secondary objective will be to compare the cost effectiveness of these two prophylactic
regimens.
Phase:
Phase 3
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Enzon Pharmaceuticals, Inc.
Treatments:
Amphotericin B Liposomal amphotericin B Posaconazole